Suppr超能文献

注射用和口服雷尼替丁溶液的物理相容性和化学稳定性

Physical Compatibility and Chemical Stability of Injectable and Oral Ranitidine Solutions.

作者信息

Fleming Kelly, Donnelly Ronald F

机构信息

The Ottawa Hospital, Ottawa, Ontario, Canada.

出版信息

Hosp Pharm. 2019 Feb;54(1):32-36. doi: 10.1177/0018578718763085. Epub 2018 Mar 7.

Abstract

The physical compatibility and chemical stability of ranitidine hydrochloride injectable solutions and oral syrup were studied to define beyond-use dates (BUDs). Ranitidine hydrochloride injectable solutions of 25 mg/mL packaged in glass vials and 5 mg/mL in polypropylene (PP) syringes were prepared in triplicate. Samples were refrigerated and protected from light (PFL) or stored at 25°C and either exposed to light (ETL) or PFL. Ranitidine hydrochloride oral syrup 15 mg/mL in unit-dose amber PP syringes were prepared in triplicate and then kept at 25°C. Samples were collected at days 0, 7, 14, 28, 56, and 91. Additional samples were collected at 6 months and at 6, 9, and 12 months for the 25 mg/mL solution and oral syrup, respectively. Physical parameters of pH, clarity, and color were obtained at each collection time. A validated stability-indicating high-performance liquid chromatography (HPLC) method was used to determine the chemical stability. Formulations had no significant change in pH or clarity. Although some samples yellowed, this was not associated with a decrease in concentration. The 25 mg/mL solution remained above 98.6% for 6 months, whereas the 5 mg/mL solution remained above 93.5% for 91 days under all storage conditions. At 25°C, the oral syrup retained greater than 98.8% for 12 months. The ranitidine hydrochloride injectable solutions were stable for 6 months and 91 days under the 3 storage conditions, respectively, for the 25 mg/mL solution in glass vials and 5 mg/mL solution in PP syringes. The 15 mg/mL oral syrup in unit-dose amber PP syringes was stable for 12 months at 25°C and PFL.

摘要

研究了盐酸雷尼替丁注射液和口服糖浆的物理相容性及化学稳定性,以确定其使用期限(BUDs)。制备了一式三份包装于玻璃小瓶中的25 mg/mL盐酸雷尼替丁注射液及装于聚丙烯(PP)注射器中的5 mg/mL盐酸雷尼替丁注射液。样品冷藏并避光保存(PFL),或于25°C保存,分为光照(ETL)或避光(PFL)两组。制备了一式三份装于单剂量琥珀色PP注射器中的15 mg/mL盐酸雷尼替丁口服糖浆,然后于25°C保存。在第0、7、14、28、56和91天采集样品。对于25 mg/mL溶液和口服糖浆,分别在6个月时以及6、9和12个月时采集额外样品。在每次采集时间获取pH、澄清度和颜色等物理参数。采用经过验证的稳定性指示高效液相色谱(HPLC)法测定化学稳定性。制剂的pH或澄清度无显著变化。虽然一些样品变黄,但这与浓度降低无关。在所有储存条件下,25 mg/mL溶液6个月内含量保持在98.6%以上,而5 mg/mL溶液91天内含量保持在93.5%以上。在25°C下,口服糖浆12个月内含量保持在98.8%以上。对于玻璃小瓶中的25 mg/mL溶液和PP注射器中的5 mg/mL溶液,盐酸雷尼替丁注射液在3种储存条件下分别稳定6个月和91天。装于单剂量琥珀色PP注射器中的15 mg/mL口服糖浆在25°C和避光条件下稳定12个月。

相似文献

本文引用的文献

2
Stability of ranitidine in injectable solutions.雷尼替丁在注射剂中的稳定性。
Int J Pharm. 2003 Apr 30;256(1-2):109-15. doi: 10.1016/s0378-5173(03)00067-x.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验